Mitochondrial toxicity and body shape changes during nucleos(t)ide analogues administration in patients with chronic hepatitis B.

ABSTRACT: Our study purpose was to evaluate mitochondrial (mt)DNA and RNA in peripheral blood mononuclear cells (PBMCs) and body shape changes (BSC) in HBV-infected patients. mtDNA and mtRNA were measured in PBMCs. The presence of BSC was evaluated through a questionnaire and clinical evaluation. A total of 157 subjects were enrolled, of these 107 were HBV-infected patients, 54 receiving nucleoside analogues (NAs, Group A), 53 naive to antivirals (Group B) and 50 age-sex matched controls (Group C). All HBV-treated patients had negative HBV-DNA. Twenty (37,0%) received lamivudine?+?adefovir, 20 (37.0%) tenofovir, 2 (3.7%) lamivudine and 12 (22.2%) entecavir. Therapy median duration was 38 months (IQR 20-60) in NA-treated patients. Group A showed significantly higher mtDNA/nuclear (n) DNA ratio (p?=?0.000008) compared to Group C and Group B (p?=?0.002). Group B showed significantly higher mtDNA/nDNA ratio compared to Group C (p?=?0.017). Group A and B had significantly lower mtRNA/nRNA ratio compared to Group C (p?=?0.00003 and p?=?0.00006, respectively). Tenofovir and entecavir showed less impact compared to lamivudine?+?adefovir. mtDNA/nDNA ratio positively (Rho?=?0.34, p?

SUBMITTER: Madeddu G 

PROVIDER: S-EPMC7005185 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature